Literature DB >> 3443139

The effects of prazosin and propranolol in combination with thiazide diuretics on blood pressure and serum lipids: a multicentre study.

Y Goto1, T Tanabe, Y Ogasawara, Y Takei, T Fukui, I Fujimori, T Maeda, A Abe, S Iyori, T Tamura.   

Abstract

We have carried out randomized 12-week multicentre study to compare the effects of prazosin and propranolol on blood pressure and serum lipids in 70 patients with essential hypertension after a 4 week minimum period of treatment with thiazide diuretics. After 12 weeks treatment with prazosin (n = 40, 1.5-12.0 mg per day) or propranolol (n = 30, 30-120 mg per day) with diuretics there was a significant blood pressure reduction from 165.1/97.9 mmHg to 151.2/90.6 mmHg and from 167/96.5 mmHg to 153/91.9 mmHg, respectively. In the 12th week a significant decrease was noted in triglyceride and in low-density lipoprotein cholesterol (LDL + VLDL-C), but no significant effects were seen in high-density lipoprotein cholesterol (HDL-C) in patients receiving prazosin. On the other hand, a significant decrease in lecithin cholesterol acyltransferase (LCAT) was seen in patients receiving propranolol. Twenty-six of 40 patients receiving prazosin were given an additional 12 weeks of treatment. Twenty-two of 30 patients initially treated with propranolol were switched from propranolol to prazosin after 13 weeks and given prazosin up to the 24th week. At 24 weeks, the blood pressure was 149/93.0 mmHg in the prazosin group and 155/89.2 mmHg in the group which switched from propranolol to prazosin. Triglyceride remained reduced in the prazosin group at the 24th week. In the group which switched from propranolol to prazosin, triglyceride decreased significantly over the next 12 weeks.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3443139     DOI: 10.1007/BF00637627

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

Review 1.  Drug therapy. Prazosin.

Authors:  J Koch-Weser; R M Graham; W A Pettinger
Journal:  N Engl J Med       Date:  1979-02-01       Impact factor: 91.245

2.  Enzymatic determination of total serum cholesterol.

Authors:  C C Allain; L S Poon; C S Chan; W Richmond; P C Fu
Journal:  Clin Chem       Date:  1974-04       Impact factor: 8.327

3.  A colorimetric method for estimating serum triglycerides.

Authors:  M J Fletcher
Journal:  Clin Chim Acta       Date:  1968-11       Impact factor: 3.786

4.  Increase in serum-lipids during treatment of hypertension with chlorthalidone.

Authors:  R P Ames; P Hill
Journal:  Lancet       Date:  1976-04-03       Impact factor: 79.321

5.  Effects of prazosin and propranolol on blood pressure and plasma lipids in patients undergoing chronic hemodialysis.

Authors:  V N Meltzer; A P Goldberg; C A Tindira; A D Naumovich; H R Harter
Journal:  Am J Cardiol       Date:  1984-01-27       Impact factor: 2.778

6.  Physiologic evaluation of a new antihypertensive agent: prazosin HCl.

Authors:  M C Koshy; D Mickley; J Bourgiognie; M D Blaufox
Journal:  Circulation       Date:  1977-03       Impact factor: 29.690

7.  Effects of prazosin on serum lipids in patients with essential hypertension: a review of the findings presented at the Satellite Symposium on coronary heart disease: hypertension and other risk factors, Milan, 1983.

Authors:  J Lowenstein
Journal:  Am J Cardiol       Date:  1984-01-27       Impact factor: 2.778

8.  Metabolic consequences of atenolol and propranolol in treatment of essential hypertension.

Authors:  J L Day; N Simpson; J Metcalfe; R L Page
Journal:  Br Med J       Date:  1979-01-13

9.  Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions.

Authors:  M Burstein; H R Scholnick; R Morfin
Journal:  J Lipid Res       Date:  1970-11       Impact factor: 5.922

10.  Effect of propranolol and prazosin on blood lipids. The Oslo Study.

Authors:  P Leren; P O Foss; A Helgeland; I Hjermann; I Holme; P G Lund-Larsen
Journal:  Lancet       Date:  1980-07-05       Impact factor: 79.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.